AERI

Rhopressa (Rhokiinsa - EU) (netarsudil)(ROCK - rho kinase inhibitor)

ophthalmology

Stage (next event)

Expected Date

Quarterly Sales (Approved)

Feb 20 (Est)

Catalyst Info & Data Links

TITLE: Drug for Indication Quarterly Sales (Approved)

WHAT IS THE NEXT CATALYST EVENT?

  • Quarterly Sales (Approved)

WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Feb 20, 2021 (Est)

PRIOR DATA/EVENTS

PRESS RELEASES

  • Rhopressa® and Rocklatan® generated third quarter 2020 net revenues of $20.1 million, compared to $18.5 million in the third quarter of 2019, equivalent to an average of $77 per bottle, relatively consistent with the $78 per bottle in the second quarter of 2020. Shipments to wholesalers totaled 261,000 bottles during the third quarter of 2020, over 12 percent higher than the 232,500 bottles in the second quarter of 2020. Net revenues for the nine months ended September 30, 2020 totaled $58.5 million, compared to $45.2 million for the nine months ended September 30, 2019, reflecting a 29 percent increase.

  • 11-05-2020 Third Quarter Report

Mechanism of Action

MOA

Each patient living with OAG and OHT has unique treatment considerations. ROCK inhibitors, like Rhopressa®, work with the trabecular outflow pathway within the eye to reduce IOP levels and have proven to be efficacious in a variety of treatment regimens, making it possible to add versatility to more of your glaucoma patients’ treatments.1,2

How do ROCK Inhibitors work differently?
Within the trabecular meshwork, Rho kinase enzymes promote actin-myosin contraction and increase actin stress fibers and focal adhesions, increasing stiffness and causing resistance to aqueous flow.7ROCK inhibitors work at the cellular level within the trabecular outflow pathway to relax actin-myosin. This causes relaxation within the trabecular meshwork and the inner wall of Schlemm's canal, and increases vasodilation within the episcleral venous system.8 Thus, Rhopressa® decreases IOP by improving aqueous humor outflow through the trabecular meshwork1,7 and decreasing episcleral venous pressure (EVP).3

EJV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon